脆弱指数可用于临床试验样本量计算
该研究提出以脆弱指数为基础进行临床试验样本量计算,补充传统预设的α和检验效能阈值,并提供R软件包。对FAME和FAMOUS-NSTEMI试验设计的再分析显示,该方法在基于P值的检验中可获得更高检验效能,且脆弱指数检验的I类错误率更低并与情境相关。
要点
- 脆弱指数可整合进临床试验设计阶段的样本量计算。
- 该方法补充而非替代传统α和检验效能预设阈值。
- 再分析显示脆弱指数检验的I类错误率更低且情境相关。
核心结论
- 基于脆弱指数的样本量计算方法使临床医生能在试验设计阶段控制脆弱指数。
研究设计与样本
- 方法学研究,提出基于脆弱指数的新假设检验框架并构建于经典检验方法之上。
- 以心血管医学领域的FAME试验和FAMOUS-NSTEMI试验设计为案例进行再分析。
主要发现
- 该方法返回的样本量使基于P值的检验获得更高检验效能。
- 脆弱指数检验的I类错误率更低且与情境相关,相比标准检验。
临床怎么用
- 临床研究人员可在试验设计阶段使用该方法计算样本量并控制脆弱指数。
- 配套R软件包为设计和分析提供工具支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The fragility index is a clinically interpretable metric increasingly used to interpret the robustness of clinical trials results that is generally not incorporated in sample size calculation and applied post-hoc. In this manuscript, we propose to base the sample size calculation on the fragility index in a way that supplements the classical prefixed alpha and power cutoffs and we provide a dedicated R software package for the design and analysis tools. STUDY DESIGN AND SETTING: This approach follows from a novel hypothesis testing framework that is based on the fragility index and builds on the classical testing approach. As case studies, we re-analyse the design of two important trials in cardiovascular medicine, the FAME and FAMOUS-NSTEMI trials. RESULTS: The analyses show that approach returns sample sizes which results in a higher power for the P value based test and most importantly a lower and context dependent Type I error rate for the fragility index based test compared to standard tests. CONCLUSION: Our method allows clinicians to control for the fragility index during clinical trial design.
引用
- Baer BR, Gaudino M, Fremes SE, et al. The fragility index can be used for sample size calculations in clinical trials. J Clin Epidemiol. 2021. PMID: 34403756. doi:10.1016/j.jclinepi.2021.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。